Angiotensin Converting Enzyme Inhibition in Children With Mitral Regurgitation

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Heart Defects, Congenital, Heart Septal Defects, Ventricular, Heart Failure, Congestive

In brief

This study will evaluate the efficacy and safety of angiotensin converting enzyme inhibition (ACE-I) therapy for the treatment of mitral regurgitation (MR).

Key facts

Study ID

NCT00113698

Run by

University of Utah

People needed

5

Starts

2004-12-01

Expected to finish

2006-01-01

Last updated by the study team

2014-03-13

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children less than 18 years of age and at least 6 months post AVSD repair or reoperation
• At least moderate MR
• Asymptomatic or minimally symptomatic, defined by Ross Heart Failure Class I or II
• Atrioventricular synchrony (paced or intrinsic)

You may not qualify if…

• Tetrology of Fallot, total or partial anomalous venous connection
• More than trivial MS or outflow obstruction
• Other sources of LV volume overload
• Hypertrophic obstructive cardiomyopathy
• Significant residual coarctation

Where it is running

• Children's Hospital Boston — Boston, Massachusetts, United States
• Columbia College of Physicians and Surgeons — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Primary Children's Hospital — Salt Lake City, Utah, United States
• Hospital for Sick Children — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.